Halozyme Therapeutics (HALO) Q1 2025 earnings summary

Executive summary

• Achieved 35% year-over-year revenue growth to $265 million in Q1 2025, with net income up 54% to $118 million and adjusted EBITDA up 40% to $162 million, driven by blockbuster products and 11 new growth catalysts.

• Announced a $250 million share repurchase for 2025, building on $1.55 billion deployed since 2019 and reducing shares outstanding by 10%.

• Multiple new product launches, regulatory approvals, and label expansions across key partnered brands in the U.S., EU, and China.

• Pipeline and platform expansion includes new auto injector agreements and several active development programs, positioning for sustained long-term growth.

• Filed a patent infringement lawsuit against Merck in April 2025.

Financial highlights

• Total revenue for Q1 2025 was $265 million, up from $195.9 million in Q1 2024; royalty revenue increased 39% to $168 million.

• Product sales grew 33% to $78 million; collaboration revenue reached $19 million (+12% YoY).

• Adjusted EBITDA was $162 million (+40% YoY); GAAP diluted EPS was $0.93 (up 55% YoY); non-GAAP diluted EPS was $1.11 (up 41%).

• Operating income rose 48% to $142 million; free cash flow was $153 million in Q1; cash and equivalents at $747.9 million as of March 31, 2025.

• Cost of sales increased to $48.4 million, primarily due to higher product sales.

Outlook and guidance

• 2025 revenue guidance raised to $1.2–$1.28 billion, up 18–26% year-over-year; royalty revenue expected at $750–$785 million (31–37% growth); product sales at $340–$365 million.

• Adjusted EBITDA projected at $790–$840 million (25–33% growth); non-GAAP EPS at $5.30–$5.70.

• Multi-year projections show total revenue, adjusted EBITDA, and non-GAAP EPS expected to double from 2024 to 2028.

• Sequential quarterly growth expected in royalties; product sales and collaboration revenue weighted to the second half.

• Current liquidity is expected to fund operations for at least the next 12 months.